ESCRS - PO1062 - Oral Apx3330 Reduces The Drss Worsening After 24-Weeks Of Daily Treatment: Efficacy And Safety Results Of The Zeta-1 Phase 2 Trial In Diabetic Retinopathy

Oral Apx3330 Reduces The Drss Worsening After 24-Weeks Of Daily Treatment: Efficacy And Safety Results Of The Zeta-1 Phase 2 Trial In Diabetic Retinopathy

Published 2023 - 41st Congress of the ESCRS

Reference: PO1062 | Type: Free paper | DOI: 10.82333/na1k-4710